The impact of statin use on pneumonia risk and outcome: A combined population-based case-control and cohort study

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Nielsen, Anders G ^a   Nielsen, Rikke B ^a   Riis, Anders H ^a   Johnsen, Søren P ^a   Sørensen, Henrik T ^a   Thomsen, Reimar W ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AWARENESS; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DENMARK; DRUG THERAPY; DRUG USE; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK; SEX; SOCIOECONOMICS; SURGERY; CASE CONTROL STUDY; HOSPITAL MORTALITY; MIDDLE AGED; REGISTER;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PNEUMONIA; PREVALENCE; REGISTRIES; RISK;

EID: 84863661179     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11418     Document Type: Article

References (39)

1. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007, 7:358-368. 10.1016/S1473-3099(07)70111-1, 17448939.
2. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413. 10.1016/j.atherosclerosis.2005.12.022, 16443229.
3. McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007, 98:163-175. 10.1093/bja/ael358, 17251210.
4. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kubo M, Murakami M, Hata Y, Kohno K, Morita H, Kusano KF, Ito H. Impact of hypertriglyceridemia on endothelial dysfunction during statin +/- ezetimibe therapy in patients with coronary heart disease. Am J Cardiol 2011, 108:333-339. 10.1016/j.amjcard.2011.03.049, 21545981.
5. Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med 2010, 104:1081-1091. 10.1016/j.rmed.2010.04.005, 20447815.
6. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010, 25:656.e7-656.e22.
7. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009, 15:325-334. 10.1111/j.1469-0691.2009.02750.x, 19416304.
8. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008, 61:774-785. 10.1093/jac/dkn019, 18263570.
9. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667. 10.1001/archinternmed.2009.286, 19822822.
10. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006, 61:957-961. 10.1136/thx.2006.062885, 2121156, 16809409.
11. Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007, 27:325-332. 10.1592/phco.27.3.325, 17316144.
12. Myles PR, Hubbard RB, McKeever TM, Pogson Z, Smith CJ, Gibson JE. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf 2009, 18:269-275. 10.1002/pds.1715, 19235776.
13. Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract 2011, 61:e742-748. 10.3399/bjgp11X606654, 22054338.
14. Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ 2009, 338:b2137. 10.1136/bmj.b2137, 2697311, 19531550.
15. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008, 168:2081-2087. 10.1001/archinte.168.19.2081, 18955636.
16. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005, 6:82. 10.1186/1465-9921-6-82, 1199623, 16042797.
17. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012. 10.1378/chest.06-1997, 17426203.
18. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, Pugh JA. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008, 31:611-617. 10.1183/09031936.00162006, 17959631.
19. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008, 121:1002-1007. e1001, 10.1016/j.amjmed.2008.06.030, 18954848.
20. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011, 342:d1642. 10.1136/bmj.d1642, 3071610, 21471172.
21. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, Farley MM, Ryan P, Lynfield R, Baumbach J, Schaffner W, Bennett N, Zansky S. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012, 205:13-19. 10.1093/infdis/jir695, 22170954.
22. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK. Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 2012, 27:280-286. 10.1007/s11606-011-1826-2, 21842322.
23. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006, 333:999. 10.1136/bmj.38992.565972.7C, 1635620, 17060337.
24. Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA, Angus DC. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39:1871-1878. 10.1097/CCM.0b013e31821b8290, 3139804, 21516038.
25. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, Sutherland J, Brookhart MA. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009, 119:2051-2057. 10.1161/CIRCULATIONAHA.108.824151, 2744446, 19349320.
26. Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by 'healthy user' effect. BMJ 2006, 333:980-981. 10.1136/bmj.39024.513218.BE, 1635648, 17095760.
27. International Statistical Classification of Diseases, 10th Revision(ICD-10). Geneva, Switzerland:World Health Organisation., http://apps.who.int/classifications/icd10/browse/2010/en
28. Dansk Lægemiddel Information A/S homepage. Danish., http://medicin.dk/
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. 10.1016/0021-9681(87)90171-8, 3558716.
30. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003, 56:221-229. 10.1016/S0895-4356(02)00585-1, 12725876.
31. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619. 10.1016/0895-4356(92)90133-8, 1607900.
32. Rothman KJ. Modern Epidemiology 1998, Philadelphia, PA: Lippincott Williams & Wilkins.
33. Austin PC, Anderson GM, Cigsar C, Gruneir A. Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision. Pharmacoepidemiol Drug Saf 2012, 21:714-724. 10.1002/pds.3299, 22653805.
34. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009, 35:1255-1260. 10.1007/s00134-009-1429-0, 19205663.
35. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 2011, 32:2525-2532. 10.1093/eurheartj/ehr333, 21873710.
36. Thomsen RW, Riis A, Norgaard M, Jacobsen J, Christensen S, McDonald CJ, Sorensen HT. Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. J Intern Med 2006, 259:410-417. 10.1111/j.1365-2796.2006.01629.x, 16594909.
37. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997, 44:445-448.
38. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002, 53:375-378. 10.1046/j.1365-2125.2002.01563.x, 1874277, 11966668.
39. Thomsen RW, Nielsen RB, Nørgaard M, Horsdal HT, Larsen FB, Sørensen HT. Lifestyle profile among statin users. Presented at: 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; 14-17 August 2011; Chicago, IL. Abstract 258